These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2893451)

  • 21. Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis.
    Rojkovich B; Hodinka L; Bálint G; Szegedi G; Varjú T; Tamási L; Molnár E; Szilágyi M; Szocsik K
    Scand J Rheumatol; 1999; 28(4):216-21. PubMed ID: 10503557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].
    Yukawa N; Mimori T
    Clin Calcium; 2009 Mar; 19(3):395-403. PubMed ID: 19252250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis.
    Mulder CJ; Tytgat GN; Weterman IT; Dekker W; Blok P; Schrijver M; van der Heide H
    Gastroenterology; 1988 Dec; 95(6):1449-53. PubMed ID: 2903110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Symposium on enteric-coated sulphasalazine in rheumatoid arthritis. Proceedings of a symposium. London, December 6, 1985.
    Drugs; 1986; 32 Suppl 1():1-80. PubMed ID: 2877848
    [No Abstract]   [Full Text] [Related]  

  • 25. Non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Effects on clinical parameters and cellular immunity.
    Førre O; Thoen J; Helgetveit K; Haile Y
    Inflammation; 1984 Jun; 8 Suppl():S109-13. PubMed ID: 6480068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan.
    Ali AA; Iqbal MP; Hussain MA; Mehboobali N; Beg JA; Rahbar MH
    J Pak Med Assoc; 1998 Jan; 48(1):3-6. PubMed ID: 9610077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.
    Rains CP; Noble S; Faulds D
    Drugs; 1995 Jul; 50(1):137-56. PubMed ID: 7588084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Basic therapy of rheumatoid arthritis. Comparison of methotrexate and sulfasalazine].
    Keitel W; Keitel R; Pap T
    Z Gesamte Inn Med; 1993 Oct; 48(10):480-3. PubMed ID: 7903012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulphasalazine therapy in rheumatoid arthritis. A two-year study and follow-up of clinical results.
    Georgescu C
    Rom J Intern Med; 1992; 30(2):127-32. PubMed ID: 1353901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy in rheumatoid arthritis.
    Schwarzer AC; Arnold MH; Brooks PM
    Baillieres Clin Rheumatol; 1990 Dec; 4(3):663-85. PubMed ID: 1982708
    [No Abstract]   [Full Text] [Related]  

  • 31. [Armentarium and strategies for the treatment of rheumatoid arthritis].
    Lioté F
    Rev Prat; 2005 Dec; 55(19):2146-60. PubMed ID: 16544925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
    O'Dell JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sulfasalazine (Azulfidine RA) versus aurothioglucose in therapy of chronic polyarthritis--status report of an open, comparative, multicenter long-term study].
    Schattenkirchner M
    Z Rheumatol; 1987; 46(2):67-70. PubMed ID: 2885986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical therapy: where are we now?
    Resman-Targoff BH
    Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S11-8. PubMed ID: 16960243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial.
    Pinals RS; Kaplan SB; Lawson JG; Hepburn B
    Arthritis Rheum; 1986 Dec; 29(12):1427-34. PubMed ID: 2879544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
    Korpela M; Laasonen L; Hannonen P; Kautiainen H; Leirisalo-Repo M; Hakala M; Paimela L; Blåfield H; Puolakka K; Möttönen T;
    Arthritis Rheum; 2004 Jul; 50(7):2072-81. PubMed ID: 15248204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New basic preparations with prolonged action in the treatment of rheumatoid arthritis].
    Tumanova IG; Sigidin IaA
    Ter Arkh; 1987; 59(4):80-3. PubMed ID: 2884735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis.
    Narayan N; Rigby S; Carlucci F
    Clin Rheumatol; 2017 Feb; 36(2):477-479. PubMed ID: 27778097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical studies with salazopyrine--consequences and perspectives].
    Zeidler H
    Z Rheumatol; 1987; 46(2):59-66. PubMed ID: 2885985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.